newsfilter
← Latest News
GlobeNewswire·

Vincerx Pharma Announces FDA Clearance of IND for VIP943

Phase 1 trial expected to begin in early Q4 2023 VIP943 is Vincerx' first candidate from next-generation ADC platform and its second IND clearance within 8 months, highlighting Vincerx's development and regulatory